---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-127487"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:37:56.291591+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cellectar pivots away from iopofosine I 131 accelerated approval; cuts workforce 60%

## Summary
- Due to FDA Type-C meeting, accelerated approval for iopofosine I 131 would now require randomized confirmatory study with PFS endpoint; company seeking strategic options for this program.
- Workforce cut ~60%; expects annual operating cost savings of ~$7.5M and ~$1.7M severance costs in Q4 2024/Q1 2025.
- Shifting focus to alpha- (CLR 121225) and Auger-emitter (CLR 121125) programs; expects to file IND applications in H1 2025 for Phase 1 solid tumor studies.
- Restructuring expected to extend cash runway into Q3 2025 from earlier depletion estimate.

## SEC filing metadata
- accession: 0001104659-24-127487
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/0001104659-24-127487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/tm2430732d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-127487
- JSON: https://secwatch.observer/filing/0001104659-24-127487.json
- Plain text: https://secwatch.observer/filing/0001104659-24-127487.txt

## Key facts
- Restructurings & Charges
  Cellectar Biosciences, Inc. announced a restructuring with charges of approximately $1.7 million affecting overall workforce (approximately 60%).
  - Type: restructuring
  - Charge: approximately $1.7 million
  - Affected area: overall workforce
  - Headcount: approximately 60%
  source text: will decrease its annual operating costs by approximately $7.5 million. Additionally, the Company estimates that it will incur aggregate severance costs of approximately $1.7 million, which will be recorded primarily in the fourth quarter of 2024 and first quarter of 2025. The cost that the Company expects to incur in connection with the workforce reduction
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/0001104659-24-127487-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.